不同药物治疗对高血压患者微量蛋白尿的影响分析

目的探讨不同药物治疗对高血压患者微量蛋白尿的影响。方法高血压伴发肾损害患者80例,根据患者意愿分为治疗组40例与对照组40例,在常规对症治疗基础上,对照组服用缬沙坦治疗,治疗组采用替米沙坦治疗。结果治疗后两组SBP、DBP值和尿微量白蛋白值都有了大幅度地降低(P<0.05),治疗组上述三个指标均明显少于对照组(P<0.05)。结论血管紧张素受体拮抗剂是治疗高血压伴发肾损害的主要药物,其中替米沙坦可以更加有效降低血压,同时降低尿微量白蛋白含量。

Analysis of Effect of Treating Hypertension Patients with Valsartan and Telmisartan

Objective To investigate effect of treating hypertension patients with different medicines. Methods Totally 80 patients with hypertension associated with renal damage were divided into treatment group and control group （each 40 cases） based on their own requests. On the basis of conventional therapy, control group were treated with valsartan, but treatment group with micardis. Results After treatment, both groups had dramatically lower SBP, DBP and microalbuminuria values （P〈0.05）. However, treatment group had remarkably decreases （P〈0.05） in all the three indexes than control group. Conclusion Angiotensin receptor antagonist is a major medicine for treating hypertension associated with renal damage. And in such antagonists, telmisartan more effectivelyreduces hypertension and microalbuminuria content.